Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms

PURPOSE: Netarsudil is a Rho kinase/norepinephrine transporter inhibitor currently in phase 3 clinical development for glaucoma treatment. We investigated the effects of its active metabolite, netarsudil-M1, on outflow facility (C), outflow hydrodynamics, and morphology of the conventional outflow p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Ruiyi, Li, Guorong, Le, Thuy Duong, Kopczynski, Casey, Stamer, W. Daniel, Gong, Haiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2016
Materias:
Glaucoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114035/
https://www.ncbi.nlm.nih.gov/pubmed/27842161
http://dx.doi.org/10.1167/iovs.16-20189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114035/
https://www.ncbi.nlm.nih.gov/pubmed/27842161
http://dx.doi.org/10.1167/iovs.16-20189

Ejemplares similares